Nanox to Present at Two Upcoming Investor Conferences in September 2022
NEVE ILAN, Israel, Sept. 08, 2022 (GLOBE NEWSWIRE) — NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative medical imaging technology company, today announces that Company management will participate in two investor conferences in the month of September 2022:
- LifeSci Partners HealthTech Symposium on September 20-21, 2022
- Ladenburg Thalmann Healthcare Conference on September 29, 2022
About LifeSci Partners HealthTech Symposium
Nanox’s Chief Executive Officer, Erez Meltzer, and Chief Financial Officer, Ran Daniel, will deliver a presentation during the LifeSci Partners HealthTech Symposium, which will be held on September 20-21, 2022.
The presentation is scheduled for Wednesday, September 21st at 8:30 am Eastern Time and will be accessible via a live webcast here. A replay of presentation will be available after the conclusion of the live presentation on the Investor Relations section of the Company’s website.
About Ladenburg Thalmann Healthcare Conference
Nanox’s Chief Executive Officer, Erez Meltzer, and Chief Financial Officer, Ran Daniel, will deliver a presentation and host investor 1×1 meetings during the Ladenburg Thalmann Healthcare Conference, which will be held at the Sofitel Hotel New York on September 29th, 2022.
The presentation is scheduled for Thursday, September 29th at 4:30 pm Eastern Time and will be accessible via a live webcast here. The webcast replay will be available after the conclusion of the live presentation on the Investor Relations section of the Company’s website.
About Nanox
Nanox-X Imaging Ltd (NASDAQ: NNOX) is focused on applying its proprietary medical imaging technology and solutions to make diagnostic medicine more accessible and affordable across the globe. The vision of Nanox is to increase the early detection of medical conditions that are discoverable by medical imaging technologies based on X-ray, by improving access to imaging, reducing imaging costs and enhancing imaging efficiency, which Nanox believes is key to increasing early prevention and treatment, improving health outcomes, and, ultimately, saving lives. Nanox is developing a holistic imaging solution, which includes the Nanox System, comprised of the Nanox.ARC using its novel MEMs X-ray source technology and the Nanox.CLOUD, a companion cloud software, integrated with AI solutions and teleradiology services. For more information, please visit www.nanox.vision.
Forward-Looking Statements:
This press release may contain forward-looking statements that are subject to risks and uncertainties. All statements that are not historical facts contained in this press release are forward-looking statements. Such statements include, but are not limited to, any statements relating to the initiation, timing, progress and results of the Company’s research and development, manufacturing and commercialization activities with respect to its X-ray source technology and the Nanox.Arc, the ability to realize the expected benefits of its recent acquisitions and the projected business prospects of the Company and the acquired companies. In some cases, you can identify forward-looking statements by terminology such as “can,” “might,” “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “should,” “could,” “expect,” “predict,” “potential,” or the negative of these terms or other similar expressions. Forward-looking statements are based on information the Company has when those statements are made or management’s good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Factors that could cause actual results to differ materially from those currently anticipated include: risks related to (i) Nanox’s ability to complete development of the Nanox System; (ii) Nanox’s ability to successfully demonstrate the feasibility of its technology for commercial applications; (iii) Nanox’s expectations regarding the necessity of, timing of filing for, and receipt and maintenance of, regulatory clearances or approvals regarding its technology, the Nanox.Arc and Nanox.CLOUD from regulatory agencies worldwide and its ongoing compliance with applicable quality standards and regulatory requirements; (iv) Nanox’s ability to realize the anticipated benefits of the recent acquisitions, which may be affected by, among other things, competition, brand recognition, the ability of the acquired companies to grow and manage growth profitably and retain their key employees; (v) Nanox’s ability to enter into and maintain commercially reasonable arrangements with third-party manufacturers and suppliers to manufacture the Nanox.Arc; (vi) the market acceptance of the Nanox System and the proposed pay-per-scan business model; (vii) Nanox’s expectations regarding collaborations with third-parties and their potential benefits; and (viii) Nanox’s ability to conduct business globally; (ix) changes in global, political, economic, business, competitive, market and regulatory forces; and (x) risks related to business interruptions resulting from the COVID-19 pandemic or similar public health crises, among other things.
For a discussion of other risks and uncertainties, and other important factors, any of which could cause Nanox’s actual results to differ from those contained in the Forward-Looking Statements, see the section titled “Risk Factors” in Nanox’s Annual Report on Form 20-F for the year ended December 31, 2021, and subsequent filings with the U.S. Securities and Exchange Commission. The reader should not place undue reliance on any forward-looking statements included in this press release.
Except as required by law, Nanox undertakes no obligation to update publicly any forward-looking statements after the date of this report to conform these statements to actual results or to changes in the Company’s expectations.
Investors:
Mike Cavanaugh
ICR Westwicke
IR@nanox.vision
Media:
Jon Yu
ICR Westwicke
NanoxPR@icrinc.com
Source: NANO-X IMAGING LTD
